甲硝唑乙酸酯 | 13182-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 甲硝唑乙酸酯
• 中文别名: 甲硝唑杂质15
• 英文名称: acetic acid 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester
• 英文别名: 2-(5-methyl-2-nitro-1H-imidazol-1-yl)ethyl acetate；1-(2-acetoxyethyl)-2-methyl-5-nitroimidazole；metronidazole acetate；SDS-19；1-acetoxy-2-(2-methyl-5-nitro-imidazol-1-yl)-ethane；1-(2-acetoxy-ethyl)-2-methyl-5-nitroimidazole；2-(2-methyl-5-nitroimidazol-1-yl)ethyl acetate
• CAS: 13182-82-6
• 化学式: C₈H₁₁N₃O₄
• 分子量: 213.193
• InChiKey: MQXDTGGRMOLAPU-UHFFFAOYSA-N

物化性质

• 熔点：
  71 - 73°C
• 沸点：
  397.1±22.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  甲硝唑乙酸酯 在 硫酸 作用下， 以 乙腈 为溶剂， 生成 3-nitro-8-(4-nitrophenyl)-5,6-dihydroimidazo[1,2-d][1,4]oxazepine
  参考文献：
  名称：

  Nair, M. D.; Desai, J. A., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 5, p. 338 - 340

  摘要：

  DOI：
• 作为产物：
  描述：

  乙酸酐 、 甲硝唑 在 吡啶 作用下， 反应 2.0h， 以86%的产率得到甲硝唑乙酸酯
  参考文献：
  名称：

  Dubey, Sonal; Jain, Vinod; Precthi, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 11, p. 1571 - 1576

  摘要：

  DOI：

文献信息

• Visible-light-promoted late-stage direct fluoroalkylation of nitroimidazoles
  作者：Hezhen Wang、Zhiyuan Wang、Chunyong Wei、Guohui Bai、Yongzheng Chen、Jing Wang、Lei Zhang

  DOI：10.1016/j.tetlet.2021.153484

  日期：2021.11

  nitroimidazoles through visible-light-prompted direct radical reaction with commercially available materials is described. The strategy proceeds smoothly under mild conditions to afford the fluoroalkyl nitroimidazoles under mild conditions. In addition, control experiments have been performed, revealing a radical process involved in the reaction mechanism. Preliminary evaluations on some products display

  将氟烷基并入生物活性化合物可以显着改变其理化和生理特性，并进一步改善其药代动力学和药理特性。因此，氟烷基化已被公认为药物化学中用于药物发现的重要策略。在这项研究中，描述了一种通过可见光促进的直接自由基反应与市售材料制备氟烷基化硝基咪唑的有效和方便的方法。该策略在温和条件下顺利进行，在温和条件下得到氟烷基硝基咪唑。此外，还进行了对照实验，揭示了反应机理中涉及的自由基过程。
• Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines
  申请人：YAMANOUCHI EUROPE B.V.

  公开号：EP0490450A1

  公开（公告）日：1992-06-17

  Heterocyclic carboxylic esters or derivatives thereof, comprising a β-lactam moiety linked by a carboxylic acid bridge to an imidazole moiety for use as antimicrobial agents are provided. Also methods for the preparation of these esters are provided. Use of the heterocyclic carboxylic esters in methods of treatment of the human body are included, as well as pharmaceutical compositions containing these esters and the preparation thereof.

  提供了由β-内酰胺基团通过羧酸桥连接到咪唑基团的杂环羧酸酯或其衍生物，用作抗微生物剂。同时提供了这些酯的制备方法。包括在人体治疗方法中使用杂环羧酸酯，以及含有这些酯及其制备的药物组合物。
• Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications
  申请人：Milankovits Marton

  公开号：US20050208152A1

  公开（公告）日：2005-09-22

  Compositions having synergistic effective amounts of one or more antibacterial agents, a nitroimidazole, and/or a sulfonamide or a molecule or compound having folic acid antagonist effect and nitroimidazole substitution in addition, with or without an antifungal agent effective against a Candida species. The compositions are particularly useful in the treatment of genitourinary infections and their extragenital complications. Vaccination against pathogen microbes of the vagina provides a stronger and longer immune response, then the infection.

  具有协同有效量的抗菌剂、硝基咪唑和/或磺胺类化合物或具有叶酸拮抗剂作用和硝基咪唑取代的分子或化合物的组合物，有或没有对抗念珠菌属菌有效的抗真菌剂。该组合物特别适用于治疗泌尿生殖感染及其非生殖并发症。针对阴道病原微生物的疫苗接种提供了比感染更强且更持久的免疫反应。
• Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications
  申请人：Marton Milankovits

  公开号：US20090124593A1

  公开（公告）日：2009-05-14

  Compositions having an effective amount of an antibacterial agent may be useful in the treatment of amyotrophic lateral sclerosis (ALS). The compositions may include an extraordinary amount of the antibacterial agent.

  含有有效量抗菌剂的组合物可能对治疗肌萎缩侧索硬化症（ALS）有用。这些组合物可能包含超常量的抗菌剂。
• Compounds
  申请人：Klaveness Jo

  公开号：US20080103110A1

  公开（公告）日：2008-05-01

  The invention provides a water-soluble prodrug compound comprising a therapeutically effective moiety coupled via a metabolically cleavable bond to a protein binding moiety, wherein said therapeutically effective moiety has an anticancer, antiinflammatory, antiinfective or antipain effect, said protein binding moiety binds non-covalently to blood proteins, and the protein binding of said compound is at least 100% higher than that of the therapeutically effective moiety itself, with the exclusion of (i) the monoester of gemcitabine with azelaic acid, (ii) the monoester of dideoxycytidine with 1,12-dodecanedicarboxylic acid, (iii) 2-amino-1,9-dihydro-9(2′-(1-(10-acetyl-decanoyloxy)ethoxymethyl))-guanine, (iv) 5′-cytarabine monoester with 1,4-phenylene diacetic acid, (v) the monoester of metronidazole with 1,4-butanedicarboxylic acid, and (vi) the monoester of metronidazole with 1,6-phenylene diacetic acid; and pre-prodrugs metabolizable thereto.

  本发明提供了一种水溶性前药化合物，其包括通过代谢可裂解键与蛋白结合基团耦合的治疗有效基团，其中所述治疗有效基团具有抗癌、抗炎、抗感染或抗疼痛作用，所述蛋白结合基团与血液蛋白非共价结合，且所述化合物的蛋白结合至少比治疗有效基团本身高100％，不包括（i）阿齐拉酸与吉西他滨的单酯，（ii）1,12-十二烷二羧酸与二脱氧胞苷的单酯，（iii）2-氨基-1,9-二氢-9（2′-（1-（10-乙酰基癸酰氧）乙氧甲基）-鸟嘌呤，（iv）1,4-苯二乙酸单酯的5′-胞嘧啶，（v）1,4-丁二酸单酯的甲硝唑，以及（vi）1,6-苯二乙酸单酯的甲硝唑；以及可代谢为前药的前前药。